Elicio Therapeutics, Inc.
Develops lymph node-targeted immunotherapies for aggressive, KRAS-driven cancers.
ELTX | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 451 D STREET, 5TH FLOOR, 2210 BOSTON
- Website:
- https://elicio.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. The company's proprietary Amphiphile (AMP) platform is engineered to deliver vaccines, immunomodulators, and adjuvants directly to the lymph nodes. This targeted-delivery approach aims to generate a robust and durable T cell response to fight aggressive tumors. Elicio's pipeline is primarily focused on developing treatments for high-prevalence cancers, with a particular emphasis on KRAS-driven malignancies such as pancreatic ductal adenocarcinoma (PDAC).
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Elicio Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Elicio Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Elicio Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
